Medigene AG confirms final subscription price for new shares and final conversion price for convertible bonds

Not for release, publication or distribution in the United States, Australia, Canada or Israel

Press Release


Martinsried/Munich, 10 July 2014. Medigene AG (MDG1, Frankfurt, Prime Standard) announces that the final subscription price for the planned issue of new shares and the final conversion price of the convertible bonds to be issued will be EUR 5.00 per share. Thus the final subscription and conversion prices correspond to the expected subscription and conversion prices as announced in the rights offering.

The final subscription price applies to the up to 3,016,028 new shares from the capital increase against cash contribution decided and announced by Medigene on 27 June 2014. The final subscription price was calculated using the calculation method defined in the rights offering for the subscription of new shares dated 30 June 2014.

The final conversion price applies to the zero-coupon bonds at a total nominal amount of up to EUR 13,749,996.00, divided into a maximum of 13,749,996 bonds at a nominal amount of EUR 1.00 each, the issue of which Medigene decided and announced on 27 June 2014. The final conversion price was calculated using the calculation method defined in the rights offering for the subscription of new convertible bonds dated 30 June 2014.

For further details on the planned issue of new shares and convertible bonds, please see the Medigene press release dated 27 June 2014 and further information at

Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. Medigene concentrates on the development of personalized T cell immunotherapies with focus on haematological malignancies. Medigene is the first German biotech company to have revenues from a marketed product, which is distributed by commercial partners. Medigene has various drug candidates in clinical development and it is developing highly innovative treatment platforms. For more information, please visit

Note: These materials do not constitute an offer of securities for sale or a solicitation of an offer to purchase securities in the United States, Germany or any other jurisdiction.  The shares (the "Shares") of Medigene AG (the "Company") and the convertible bonds in relation to shares in Medigene AG (the "Convertible Bonds") may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended.  The Company does not intend to register any portion of the offering in the United States or to conduct a public offering of Shares or of the Convertible Bonds in the Company in the United States.

This publication constitutes neither an offer to sell nor a solicitation to buy securities. The offer will be made solely by means of, and on the basis of, a securities prospectus which is to be published. The securities prospectus will be available free of charge from Medigene AG, Lochhamer Strasse 11, 82152 Planegg/Martinsried, Germany, as well as on the Medigene AG website under

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

Contact Medigene
Julia Hofmann, Anja Clausnitzer
Tel.: +49 - 89 - 20 00 33 - 33 01

To unsubscribe from the press release distribution list, please visit: